The novel monoclonal antibody dupilumab [6] (approved in 2017 by the U.S. Food and Drug Administration for AD), targeting and blocking the IL-4 and IL-13 molecules, has shown great efficacy in treating AD and especially in rapidly improving AD-associated symptoms such as chronic itching [7]. The gene discussed is IL4; the disease is Alzheimer disease.